Idiopathic Intracranial Hypertension Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023
Global Idiopathic Intracranial Hypertension Therapeutics Market: About this market
Technavio’s idiopathic intracranial hypertension market analysis considers sales from carbonic anhydrase inhibitors and other drug classes products. Our study also finds the sales of idiopathic intracranial hypertension in Asia, Europe, North America, and ROW. In 2018, the carbonic anhydrase inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as improved vision and decreased intracranial pressure and papilledema will play a significant role in the carbonic anhydrase inhibitors segment to maintain its market position. Also, our global idiopathic intracranial hypertension market report looks at factors such as rising incidences of idiopathic intracranial hypertension, increasing morbidity and mortality rates associated with heart diseases, and identification of risk factors associated with idiopathic intracranial hypertension. However, the asymptomatic nature of disease, limited patient pool, side effects associated with idiopathic intracranial hypertension therapeutics may hamper the growth of the idiopathic intracranial hypertension industry over the forecast period.
Global Idiopathic Intracranial Hypertension Therapeutics Market: Overview
Rising incidences of idiopathic intracranial hypertension
Developed economies such as the US and other countries are witnessing a high incidence of obesity and cardiovascular disorders, which has increased the patient pool for idiopathic intracranial hypertension. This has increased the need for immediate therapeutic interventions such as idiopathic intracranial hypertension therapeutics. Thus, the rising incidence of idiopathic intracranial hypertension will lead to the expansion of the global milk chocolate market at a CAGR of almost 3% during the forecast period.
Increasing number of awareness campaigns.
The global idiopathic intracranial hypertension therapeutics market is expected to benefit from the increasing number of awareness activities that are being undertaken by public and private organizations across the world. For instance, IIH UK, a forum managed by Rare Disease Europe (EURORDIS), helps patients with idiopathic intracranial hypertension in managing their condition. EURORDIS helps increase awareness about rare diseases and focuses on improving the health of patients with rare diseases. The organization conducts specialized social services and facilitates R&D and healthcare policies. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global idiopathic intracranial hypertension market during the forecast period 2019-2023, click here.
With the presence of a few major players, the global idiopathic intracranial hypertension market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading idiopathic intracranial hypertension manufacturers, that include AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
Also, the idiopathic intracranial hypertension market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook